Why the study?
Does combination therapy (thrombus aspiration, high-dose statin, intracoronary adenosine, and GP IIb/IIIa inhibitor) reduce the incidence of no-reflow in patients with STEMI at high risk of no-reflow undergoing primary PCI?
Does combination therapy (thrombus aspiration, high-dose statin, intracoronary adenosine, and GP IIb/IIIa inhibitor) reduce the incidence of no-reflow in patients with STEMI at high risk of no-reflow undergoing primary PCI?
A combination of thrombus aspiration, high-dose statins, intracoronary adenosine, and GP IIb/IIIa inhibitors may reduce no-reflow in high-risk STEMI patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
Supports combination no-reflow prevention in high-risk STEMI PCI; extends single-agent data to multimodal strategy.
Combination of thrombus aspiration, high-dose statin pre-treatment, intracoronary administration of adenosine during PCI procedure and platelet membrane glycoprotein IIb/IIIa receptor antagonist reduce the incidence of no-reflow after primary PCI in patients with acute myocardial infarction who are at high risk of no-reflow.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2015) studied this question.